GentaGel
Slow-release Antibiotic Treatment
Startup Pre-Funding Health Tech & Life Sciences Est. 2021
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
3
1-10 employees
Confidence
86/100
About
GentaGel develops a local slow-release antibiotic treatment, which is injected and continuously releases antibiotics for up to 60 days. The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area. GentaGel provides an effective antibiotic treatment while avoiding systemic side-effects and expensive cost-of-care. The company is based on a ground-breaking drug delivery technology invented by Prof. Domb, for the in-situ sustained release of antibiotics for the treatment and prevention of surgical site infections.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Core Technology
Materials & SubstancesPolymers
Target Customer
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcareProvidersMedical Devices IndustryMedical Products
Business Model
B2C
Tags
polymersantibioticspharmaceuticalsinfection
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
6
Founded
2021
Registrar
516427762
Locations
HaKalanit St 10, Jerusalem, Israel
Links
Admin
Last Update
Aug 24, 2023
Verified by
Yanina Wainscheinker
Missing
video or image, funding rounds, news, markets, external profiles, not claimed
Team (3)
Abraham Domb
Co-founder
Founder
Eli Lerner
COO
Ido Agmon
Business Development Manager
Internal
Created by
Matan Eblagon (matane@sncentral.org)
Created
2023-07-27T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)